Purpose
Deficits in speech understanding constitute one of the most severe consequences of hearing loss. Here we investigate the clinical and genetic risk factors for symmetric deterioration of speech recognition thresholds (SRT) among cancer survivors treated with cisplatin.
Methods
SRT was measured using spondaic words and calculating the mean of measurements for both ears with symmetric SRT values. For clinical associations, SRT‐based hearing disability (SHD) was defined as SRT≥15 dB hearing loss and clinical variables were derived from the study dataset. Genotyped blood samples were used for GWAS with rank‐based inverse normal transformed SRT values as the response variable. Age was used as a covariate in association analyses.
Results
SHD was inversely associated with self‐reported health (
p =
0.004). Current smoking (
p
= 0.002), years of smoking (
p
= 0.02), BMI (
p
< 0.001), and peripheral motor neuropathy (
p =
0.003) were positively associated with SHD, while physical activity was inversely associated with SHD (
p
= 0.005). In contrast, cumulative cisplatin dose, peripheral sensory neuropathy, hypertension, and hypercholesterolemia were not associated with SHD. Although no genetic variants had an association
p
value < 5 × 10
−8
, 22 genetic variants were suggestively associated (
p
< 10
−5
) with SRT deterioration. Three of the top variants in 10 respective linkage disequilibrium regions were either positioned within the coding sequence or were eQTLs for genes involved in neuronal development (
ATE1
,
ENAH,
and
ZFHX3
).
Conclusion
Current results improve our understanding of risk factors for SRT deterioration in cancer survivors. Higher BMI, lower physical activity, and smoking are associated with SHD. Larger samples would allow for expansion of the current findings on the genetic architecture of SRT.